The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Celgene
Stock and Other Ownership Interests - Celgene
Travel, Accommodations, Expenses - Celgene
 
Consulting or Advisory Role - Hexal; Janssen
Research Funding - Amgen; Genzyme; Mundipharma; Roche
Travel, Accommodations, Expenses - Celgene
Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma.
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene; MorphoSys
Research Funding - Celgene (Inst)
 
Nagesh Kalakonda
Consulting or Advisory Role - Bristol-Myers Squibb; Hospira; Roche; Takeda
Research Funding - Celgene
 
Lorenz Truemper
No Relationships to Disclose
 
Hele Everaus
No Relationships to Disclose
 
Pierre Fustier
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Jonathan Jaeger
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Oliver Manzke
No Relationships to Disclose
 
Ulrich Jäger
Honoraria - Celgene
Consulting or Advisory Role - Celgene
Research Funding - Celgene
Travel, Accommodations, Expenses - Celgene